Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child

Pediatrics. 2020 Nov;146(5):e20200123. doi: 10.1542/peds.2020-0123.


Hemophilia A (HA) is a serious inherited bleeding disorder resulting from a deficiency of coagulation factor VIII (FVIII). Replacement therapy with intravenous infusion of FVIII can be associated with treatment failure in approximately one-third of patients secondary to the development of neutralizing alloantibodies (inhibitor). Emicizumab is a recombinant, humanized, bispecific monoclonal antibody that binds factor IXa and factor X and mimics FVIII. It has been licensed in many countries for the treatment of patients with HA with and without inhibitors with a favorable efficacy and safety profile. A 7-year-old child with severe HA and FVIII inhibitors, refractory to immune tolerance therapy, developed hematuria with nephrotic-range proteinuria after the first dose of emicizumab and subsequently also after a second dose 6 weeks later, which was associated with mild and transient leukopenia. Renal biopsy revealed a pattern of a full-house lupus nephritis. The patient fully and spontaneously recovered between 2 weeks after symptoms onset. In this report, we provide insights on a new and so far unreported renal complication associated to emicizumab treatment. Although emicizumab offers significant benefits for patient with HA, clinicians should be aware of this rare and potential serious renal adverse effect.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Bispecific / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Child
  • Factor VIII / immunology
  • Hemophilia A / blood
  • Hemophilia A / therapy*
  • Humans
  • Leukopenia / etiology
  • Lupus Nephritis / blood
  • Lupus Nephritis / etiology*
  • Lupus Nephritis / immunology
  • Lupus Nephritis / pathology
  • Male


  • Antibodies, Bispecific
  • Antibodies, Monoclonal, Humanized
  • emicizumab
  • F8 protein, human
  • Factor VIII